UKUK

GSK and HGS get approval for lupus drug

15.07.2011

London/Rockville - GlaxoSmithKline and its American partner Human Genome Sciences, Inc. announced today that the European Commission has granted marketing authorisation for belimumab (Benlysta) as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy. "We and GSK are committed to making Benlysta available in countries worldwide," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "We are particularly honoured to be bringing this medicine forward in Europe, where a number of key academic research institutions were very important to its clinical development." Belimumab received approval from the U.S. FDA on March 9, 2011. GSK and HGS announced approval from Health Canada on July 12, 2011. Regulatory applications have been submitted and are currently under review in Australia, Switzerland, Russia, Brazil, The Philippines, Israel, Singapore, Taiwan and Colombia. HGS and GSK have been working together on belimumab since 2006. Under the agreement, HGS had responsibility for conducting the belimumab Phase 3 trials, with assistance from GSK. The companies share equally in Phase 3/4 development costs, sales and marketing expenses, and profits of any product commercialised under the current agreement.

UKUK

01.02.2009

British healthcare cost watchdog NICE has reiterated its negative opinion on the use of Erbitux as a treatment for colorectal cancer. The monoclonal EGFR antibody marketed by German Merck KGaA in Europe is approved to treat both...

UKUK

20.01.2009

London – Drugs that clear auto-antibody-producing B cells from the bloodstream do not always lead to a marked clinical improvement of rheumatoid arthritis (RA) -- a disease characterised by inflammation, production of...

UKUK

20.10.2008

A London – Sales with monoclonal antibody drugs, which hit the a20bn mark last year, will grow to about a38bn annually by 2013, according to reports by market analysts from Datamonitor. Roche was the only company in Europe that...

UKUK

14.08.2008

London – The British Department of Health and the Association of British Pharmaceutical Industry (ABPI) have agreed to outline a new voluntary pharmaceutical price regulation scheme for the pricing of medicines prescribed in the...

UKUK

14.08.2008

London – ValiRx plc has achieved a 50% reduction of pancreatic cancer growth in a preclinical xenograph model with its RNAi drug VAL 101 that targets BCL-2.

UKUK

18.06.2008

A London – As tumours progress they develop ways to escape recognition and attack by cells of the immune system. However, the mechanisms used by tumours to modify the immune system are yet to be clearly determined. New...

UKUK

20.05.2008

Basingstoke/Hillørd – British biopharmaceutical company Shire plc has announced the acquisition of therapeutic candidate Metazym from Danish/Swedish company Zymenex A/S for an up-front payment of about €86m. The enzyme...

UKUK

20.05.2008

London – The British biotech sector was hit recently by two failed Phase III studies within a single week. Alizyme plc had to scrap its Renzapride treatment against irritable bowel syndrome after revealing that 55% of the...

UKUK

20.05.2008

London – Researchers from University College London have used microarray analyses to identify a key factor that distiguishes people who can fight off an infection with the hepatitis B virus (HBV) from those who cannot (J. Clin...

Displaying results 171 to 180 out of 396

< Previous 171-180 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/17/article/gsk-and-hgs-get-approval-for-lupus-drug.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.69 EUR14.47%
  • BAYER112.70 EUR6.17%
  • CO.DON3.32 EUR5.40%

FLOP

  • SYNGENTA310.90 CHF-1.96%
  • SANTHERA88.05 CHF-1.23%
  • ADDEX3.10 CHF-0.96%

TOP

  • CO.DON3.32 EUR32.8%
  • PAION3.05 EUR26.6%
  • EPIGENOMICS3.83 EUR23.2%

FLOP

  • ADDEX3.10 CHF-23.8%
  • EVOTEC3.08 EUR-15.8%
  • MEDIGENE3.93 EUR-14.6%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 19.09.2014


Current issue

All issues

Product of the week

Products